The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people living with diabetes when trying to reach and maintain their individual blood glucose
Under the agreement, Codexis employed its CodeEvolver protein engineering platform technology to develop a novel enzyme for use in its partner’s preclinical therapeutic development program. “We exceeded the performance
Oncolytic viruses are viruses engineered to kill cancer cells while sparing healthy cells, which subsequently elicits anti-cancer immune responses. This collaboration in oncolytic virus development adds another novel
Avrio, an FDA inspected facility, has the capabilities for the compounding and fill/finish of sterile clinical and commercial grade Ampligen to satisfy the Company's ongoing domestic clinical studies as
Tildrakizumab is an investigational IL-23p19 inhibitor currently being evaluated in patients with moderate-to-severe plaque psoriasis. Under terms of the license agreement, Almirall will pay Sun Pharma an initial
In response to this, Vectura has filed a patent infringement lawsuit against GSK claiming infringement of Vectura's U.S. Patent No. 8,303,991 in the United States District Court for
The National Cancer Institute (NCI), with Dr. James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI, is currently conducting a Phase
Vertex will be eligible to receive milestones and royalties based on successful development and commercialization of lomibuvir and merimepodib. Other terms were not disclosed. "Senior management at TREKtx
The FDA had no major objections to LSKB’s global phase 3 pivotal-trial study design for apatinib in patients with advanced gastric cancer. The Company believes the plan to
Espada is a wholly-owned subsidiary of Mission Pharmacal Company (Mission) and adds breadth to Mission’s established line of dermatological drug products. Prior to this acquisition, Mission offered prescription
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.